
AI-powered systematic literature review platform for researchers
Rayyan has 5 plans: a free plan, paid plans from $8.33 and custom pricing for larger teams. We have not recorded a price change.
Rayyan plans and prices
Free
$0
- Create active reviews — 3
- Invite free Reviewers — 2
- Create samples — 1
- Industry leading duplicate detection
- Get AI relevance predictions
- Analyze with workbench facets — 15+
- Access Standard support
- Limited mobile app access
Essential
custom$8.33
Billed every 3 months
$8.33/month, billed quarterly ($24.99/quarter)
- custom$8.33($8.33/month, billed quarterly ($24.99/quarter))
- monthly$8.33/mo($8.33 per month, billed quarterly)
- yearly$99.99/yr($59.88 per seat, per month, billed annually)
- Create active reviews — 3
- Invite free Reviewers — 5
- Generate PRISMA flow diagrams
- Auto-resolve duplicates
- Unlimited mobile app access
- Multi-select & bulk actions
- Programmable keyboard shortcuts
- Dark theme
Show all 9 featuresShow fewer
Advanced
custom$13.33
Billed every 3 months
$13.33/month, billed quarterly ($39.99/quarter)
- custom$13.33($13.33/month, billed quarterly ($39.99/quarter))
- monthly$13.33/mo($13.33 per month, billed quarterly)
- Create 9 active reviews — included
- Invite 10 free reviewers — included
- Create unlimited samples — included
- Extract PICO data with AI — included
- Priority support — included
Business/Academic
yearly$2,500/yr
$41.67/license/month, billed annually - starting $2,500/year for 5 licenses
- ResearchPilot AI — included
- Invite 250 free reviewers — included
- Manage teams from one dashboard — included
- Manage 50 org-wide reviews — included
- Assign workspace roles — included
- Priority support — included
Enterprise
Custom
- Boost productivity with ResearchPilot™ AI
- Add unlimited viewers
- Create unlimited reviews
- Enable SSO / SAML
- Integrate with Rayyan's API
- Control access from a management console
- Access dedicated support
Price history
Last 0 recorded changes
No price changes recorded yet.
Other AI & ML products
No confirmed alternatives yet.